{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,23]],"date-time":"2026-06-23T01:14:40Z","timestamp":1782177280566,"version":"3.54.5"},"reference-count":40,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2020,11,24]],"date-time":"2020-11-24T00:00:00Z","timestamp":1606176000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Med."],"abstract":"<jats:p>The introduction of pathogen reduction technologies (PRTs) to inactivate bacteria, viruses and parasites in donated blood components stored for transfusion adds to the existing arsenal toward reducing the risk of transfusion-transmitted infectious diseases (TTIDs). We have previously demonstrated that 405 nm violet-blue light effectively reduces blood-borne bacteria in stored human plasma and platelet concentrates. In this report, we investigated the microbicidal effect of 405 nm light on one important bloodborne parasite <jats:italic>Trypanosoma cruzi<\/jats:italic> that causes Chagas disease in humans. Our results demonstrated that a light irradiance at 15 mWcm<jats:sup>\u22122<\/jats:sup> for 5 h, equivalent to 270 Jcm<jats:sup>\u22122<\/jats:sup>, effectively inactivated <jats:italic>T. cruzi<\/jats:italic> by over 9.0 Log<jats:sub>10<\/jats:sub>, in plasma and platelets that were evaluated by a MK2 cell infectivity assay. Giemsa stained <jats:italic>T. cruzi<\/jats:italic> infected MK2 cells showed that the light-treated parasites in plasma and platelets were deficient in infecting MK2 cells and did not differentiate further into intracellular amastigotes unlike the untreated parasites. The light-treated and untreated parasite samples were then evaluated for any residual infectivity by injecting the treated parasites into Swiss Webster mice, which did not develop infection even after the animals were immunosuppressed, further demonstrating that the light treatment was completely effective for inactivation of the parasite; the light-treated platelets had similar <jats:italic>in vitro<\/jats:italic> metabolic and biochemical indices to that of untreated platelets. Overall, these results provide a proof of concept toward developing 405 nm light treatment as a pathogen reduction technology (PRT) to enhance the safety of stored human plasma and platelet concentrates from bloodborne <jats:italic>T. cruzi<\/jats:italic>, which causes Chagas disease.<\/jats:p>","DOI":"10.3389\/fmed.2020.617373","type":"journal-article","created":{"date-parts":[[2020,11,24]],"date-time":"2020-11-24T06:26:19Z","timestamp":1606199179000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":19,"title":["Complete Inactivation of Blood Borne Pathogen Trypanosoma cruzi in Stored Human Platelet Concentrates and Plasma Treated With 405 nm Violet-Blue Light"],"prefix":"10.3389","volume":"7","author":[{"given":"Katarzyna I.","family":"Jankowska","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rana","family":"Nagarkatti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nirmallya","family":"Acharyya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neetu","family":"Dahiya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caitlin F.","family":"Stewart","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruairidh W.","family":"Macpherson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark P.","family":"Wilson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John G.","family":"Anderson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Scott J.","family":"MacGregor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michelle","family":"Maclean","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neil","family":"Dey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alain","family":"Debrabant","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chintamani D.","family":"Atreya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2020,11,24]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"506","DOI":"10.1186\/s13071-019-3766-3","article-title":"Trypanosoma cruzi infection associated with atypical clinical manifestation during the acute phase of the Chagas disease","volume":"12","author":"Rangel-Gamboa","year":"2019","journal-title":"Parasit Vectors"},{"key":"B2","doi-asserted-by":"publisher","first-page":"655","DOI":"10.1128\/CMR.00005-11","article-title":"Trypanosoma cruzi and Chagas' disease in the United States","volume":"24","author":"Bern","year":"2011","journal-title":"Clin Microbiol Rev"},{"key":"B3","doi-asserted-by":"publisher","first-page":"1667","DOI":"10.3389\/fmicb.2017.01667","article-title":"Trypanosoma cruzi evades the complement system as an efficient strategy to survive in the mammalian host: the specific roles of host\/parasite molecules and Trypanosoma cruzi calreticulin","volume":"8","author":"Ramirez-Toloza","year":"2017","journal-title":"Front Microbiol"},{"key":"B4","doi-asserted-by":"publisher","first-page":"460","DOI":"10.1080\/21505594.2018.1543517","article-title":"Autophagy: a necessary process during the Trypanosoma cruzi life-cycle","volume":"10","author":"Salassa","year":"2019","journal-title":"Virulence"},{"key":"B5","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1016\/j.htct.2018.12.001","article-title":"Trypanosoma cruzi infection in transfusion medicine","volume":"41","author":"Gomez","year":"2019","journal-title":"Hematol Transfus Cell Ther"},{"key":"B6","doi-asserted-by":"publisher","first-page":"e2650","DOI":"10.1371\/journal.pntd.0002650","article-title":"Aptamer based, non-PCR, non-serological detection of Chagas disease biomarkers in Trypanosoma cruzi infected mice","volume":"8","author":"Nagarkatti","year":"2014","journal-title":"PLoS Negl Trop Dis"},{"key":"B7","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1186\/s13071-016-1315-x","article-title":"Increased mortality attributed to Chagas disease: a systematic review and meta-analysis","volume":"9","author":"Cucunuba","year":"2016","journal-title":"Parasit Vectors"},{"key":"B8","doi-asserted-by":"publisher","first-page":"1225","DOI":"10.4269\/ajtmh.16-0213","article-title":"What do we know about Chagas disease in the United States?","volume":"95","author":"Montgomery","year":"2016","journal-title":"Am J Trop Med Hyg"},{"key":"B9","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1016\/j.actatropica.2017.09.017","article-title":"Trypanosoma cruzi genetic diversity: something new for something known about Chagas disease manifestations, serodiagnosis and drug sensitivity","volume":"184","author":"Zingales","year":"2018","journal-title":"Acta Trop"},{"key":"B10","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1016\/S0037-1963(01)90118-0","article-title":"Fundamentals of the psoralen-based Helinx technology for inactivation of infectious pathogens and leukocytes in platelets and plasma","volume":"38","author":"Wollowitz","year":"2001","journal-title":"Semin Hematol"},{"key":"B11","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1128\/AAC.47.2.475-479.2003","article-title":"Trypanosoma cruzi inactivation in human platelet concentrates and plasma by a psoralen (amotosalen HCl) and long-wavelength UV","volume":"47","author":"Van Voorhis","year":"2003","journal-title":"Antimicrob Agents Chemother"},{"key":"B12","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1016\/j.transci.2007.07.002","article-title":"Pathogen inactivation of Trypanosoma cruzi in plasma and platelet concentrates using riboflavin and ultraviolet light","volume":"37","author":"Cardo","year":"2007","journal-title":"Transfus Apher Sci"},{"key":"B13","doi-asserted-by":"publisher","first-page":"1932","DOI":"10.1128\/AEM.01892-08","article-title":"Inactivation of bacterial pathogens following exposure to light from a 405-nanometer light-emitting diode array","volume":"75","author":"Maclean","year":"2009","journal-title":"Appl Environ Microbiol"},{"key":"B14","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1111\/j.1751-1097.2012.01202.x","article-title":"Sporicidal effects of high-intensity 405 nm visible light on endospore-forming bacteria","volume":"89","author":"Maclean","year":"2013","journal-title":"Photochem Photobiol"},{"key":"B15","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1016\/j.funbio.2013.05.004","article-title":"Lethal effects of high-intensity violet 405-nm light on Saccharomyces cerevisiae, Candida albicans, and on dormant and germinating spores of Aspergillus niger","volume":"117","author":"Murdoch","year":"2013","journal-title":"Fungal Biol"},{"key":"B16","doi-asserted-by":"publisher","first-page":"331","DOI":"10.3389\/fmed.2019.00331","article-title":"Non-ionizing 405 nm light as a potential bactericidal technology for platelet safety: evaluation of in vitro bacterial inactivation and in vivo platelet recovery in severe combined immunodeficient mice","volume":"6","author":"Maclean","year":"2019","journal-title":"Front Med."},{"key":"B17","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1007\/s12560-016-9275-z","article-title":"New proof-of-concept in viral inactivation: virucidal efficacy of 405 nm light against feline calicivirus as a model for norovirus decontamination","volume":"9","author":"Tomb","year":"2017","journal-title":"Food Environ Virol"},{"key":"B18","doi-asserted-by":"publisher","first-page":"e3451","DOI":"10.1371\/journal.pntd.0003451","article-title":"Aptamer-based detection of disease biomarkers in mouse models for chagas drug discovery","volume":"9","author":"De Araujo","year":"2015","journal-title":"PLoS Negl Trop Dis"},{"key":"B19","doi-asserted-by":"publisher","first-page":"e1870","DOI":"10.1371\/journal.pntd.0001870","article-title":"Fexinidazole: a potential new drug candidate for Chagas disease","volume":"6","author":"Bahia","year":"2012","journal-title":"PLoS Negl Trop Dis"},{"key":"B20","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1111\/j.1423-0410.1982.tb01067.x","article-title":"Factors influencing changes in pH during storage of platelet concentrates at 20-24 degree C","volume":"42","author":"Moroff","year":"1982","journal-title":"Vox Sang"},{"key":"B21","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1159\/000350220","article-title":"Noninvasive pH monitoring in platelet concentrates","volume":"40","author":"Doescher","year":"2013","journal-title":"Transfus Med Hemother"},{"key":"B22","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1111\/j.1423-0410.1993.tb02147.x","article-title":"Role of lactate in platelet storage lesion","volume":"65","author":"Bertolini","year":"1993","journal-title":"Vox Sang"},{"key":"B23","doi-asserted-by":"publisher","first-page":"1931","DOI":"10.1161\/01.CIR.102.16.1931","article-title":"P-selectin expression on platelets determines size and stability of platelet aggregates","volume":"102","author":"Merten","year":"2000","journal-title":"Circulation"},{"key":"B24","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1080\/09537100050129251","article-title":"Platelet annexin V: the ins and outs","volume":"11","author":"Tzima","year":"2000","journal-title":"Platelets"},{"key":"B25","doi-asserted-by":"publisher","first-page":"608","DOI":"10.1016\/j.biopha.2008.10.004","article-title":"Comparison of collagen vs. adenosine diphosphate in detecting antiplatelet effect in patients with coronary artery disease","volume":"63","author":"Li","year":"2009","journal-title":"Biomed Pharmacother"},{"key":"B26","doi-asserted-by":"publisher","first-page":"2920514","DOI":"10.1155\/2016\/2920514","article-title":"A new proof of concept in bacterial reduction: antimicrobial action of violet-blue light (405 nm) in ex vivo stored plasma","volume":"2016","author":"Maclean","year":"2016","journal-title":"J Blood Transfus"},{"key":"B27","doi-asserted-by":"publisher","first-page":"2403","DOI":"10.3389\/fmicb.2018.02403","article-title":"Evaluating the potential for resistance development to antimicrobial blue light (at 405 nm) in gram-negative bacteria: in vitro and in vivo studies","volume":"9","author":"Leanse","year":"2018","journal-title":"Front Microbiol"},{"key":"B28","doi-asserted-by":"publisher","first-page":"3002","DOI":"10.1111\/trf.15344","article-title":"Proceedings of the Food and Drug Administration public workshop on pathogen reduction technologies for blood safety 2018 (Commentary, p. 3026)","volume":"59","author":"Atreya","year":"2019","journal-title":"Transfusion."},{"key":"B29","first-page":"731","article-title":"[Effect of triphenylmethane dyes on Trypanosoma cruzi in vitro; use of gentian violet in prevention of transmission of Chagas disease by blood transfusion]","volume":"44","author":"Nussenzweig","year":"1953","journal-title":"Hospital. (Rio J)"},{"key":"B30","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1016\/0166-6851(84)90104-X","article-title":"Intracellular parasite killing induced by electron carriers. II Correlation between parasite killing and the induction of oxidative events in macrophages","volume":"13","author":"Mauel","year":"1984","journal-title":"Mol Biochem Parasitol"},{"key":"B31","doi-asserted-by":"publisher","first-page":"2104","DOI":"10.1111\/trf.13171","article-title":"Evaluation of the effectiveness of a pathogen inactivation technology against clinically relevant transfusion-transmitted bacterial strains","volume":"55","author":"Schmidt","year":"2015","journal-title":"Transfusion"},{"key":"B32","doi-asserted-by":"publisher","first-page":"2321","DOI":"10.1111\/trf.14216","article-title":"Addressing the risk of bacterial contamination in platelets: a hospital economic perspective","volume":"57","author":"Li","year":"2017","journal-title":"Transfusion"},{"key":"B33","doi-asserted-by":"publisher","first-page":"3026","DOI":"10.1111\/trf.15410","article-title":"Toward universal pathogen reduction of the blood supply (Conference Report, p. 3002)","volume":"59","author":"Marks","year":"2019","journal-title":"Transfusion."},{"key":"B34","doi-asserted-by":"publisher","first-page":"436","DOI":"10.1039\/b311900a","article-title":"Photodynamic therapy: a new antimicrobial approach to infectious disease?","volume":"3","author":"Hamblin","year":"2004","journal-title":"Photochem Photobiol Sci"},{"key":"B35","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1016\/j.tiv.2016.02.011","article-title":"Cytotoxic responses to 405nm light exposure in mammalian and bacterial cells: involvement of reactive oxygen species","volume":"33","author":"Ramakrishnan","year":"2016","journal-title":"Toxicol In Vitro"},{"key":"B36","doi-asserted-by":"publisher","first-page":"911","DOI":"10.1111\/j.1537-2995.2005.04350.x","article-title":"Effects of a new pathogen-reduction technology (Mirasol PRT) on functional aspects of platelet concentrates","volume":"45","author":"Perez-Pujol","year":"2005","journal-title":"Transfusion"},{"key":"B37","doi-asserted-by":"publisher","first-page":"653","DOI":"10.1111\/j.1537-2995.2007.01167.x","article-title":"In vitro evaluation of metabolic changes and residual platelet responsiveness in photochemical treated and gamma-irradiated single-donor platelet concentrates during long-term storage","volume":"47","author":"Apelseth","year":"2007","journal-title":"Transfusion"},{"key":"B38","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/B978-0-12-385863-4.00001-0","article-title":"Epidemiology of American trypanosomiasis (Chagas disease)","volume":"75","author":"Kirchhoff","year":"2011","journal-title":"Adv Parasitol"},{"key":"B39","doi-asserted-by":"publisher","first-page":"1913","DOI":"10.1111\/j.1537-2995.2011.03554.x","article-title":"Trypanosoma cruzi infection in North America and Spain: evidence in support of transfusion transmission","volume":"52","author":"Benjamin","year":"2012","journal-title":"Transfusion."},{"key":"B40","doi-asserted-by":"publisher","first-page":"649","DOI":"10.4049\/jimmunol.1003845","article-title":"IL-10 limits parasite burden and protects against fatal myocarditis in a mouse model of Trypanosoma cruzi infection","volume":"188","author":"Roffe","year":"2012","journal-title":"J Immunol"}],"container-title":["Frontiers in Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2020.617373\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,11,24]],"date-time":"2020-11-24T06:26:20Z","timestamp":1606199180000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2020.617373\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,11,24]]},"references-count":40,"alternative-id":["10.3389\/fmed.2020.617373"],"URL":"https:\/\/doi.org\/10.3389\/fmed.2020.617373","relation":{},"ISSN":["2296-858X"],"issn-type":[{"value":"2296-858X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,11,24]]},"article-number":"617373"}}